---
title: "Kintor Pharma climbs 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304940102.md"
description: "Kintor Pharma rose 7.53% to HK$1.500. Down 48.63% over six months and down 23.47% YTD."
datetime: "2026-11-10T02:17:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304940102.md)
  - [en](https://longbridge.com/en/news/304940102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304940102.md)
generator: "portal-rs"
---

# Kintor Pharma climbs 8%

Kintor Pharma (9939.HK) climbed nearly **8%** in Hong Kong trading to **HK$1.50**.

The stock is up 13.21% over the past five sessions, down 48.63% over the past six months and down 23.47% year to date. It sits 23.97% above its 52-week low of HK$1.210. Volume was 4.66 times its average.

The Hang Seng Index is up 4.05% over the past five sessions and down 4.49% year to date.

The company said its self-developed KX-826 tincture 1.0% has completed all subject follow-ups in a long-term safety clinical trial for androgenetic alopecia. Conducted across 12 clinical research centers nationwide with a one-year treatment period, the study demonstrated favorable safety profiles.

Kintor plans to incorporate these findings, along with positive Phase III results announced in March, into key submission materials for a new drug application to be filed with China's National Medical Products Administration.

Separately, the company received a notice of invention patent grant from the China National Intellectual Property Administration for its self-developed tyrosinase inhibitor KT-939, covering chemical structure and use. The authorization took about six months from the priority examination request, and related registration materials were submitted to the NMPA in September.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [09939.HK](https://longbridge.com/en/quote/09939.HK.md)

## Related News & Research

- [Kintor Moves to Resolve Going-Concern Audit Issue With KX-826 Commercial Push](https://longbridge.com/en/news/294548832.md)
- [Kintor Pharmaceutical Receives China Patent Grant Notice for KT-939](https://longbridge.com/en/news/302563804.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**